title: MALG vs OKT3 following renal transplantation: a randomized prospective trial.
authors.affiliation: Department of Surgery, University of Minnesota Medical School, Minneapolis.
authors.forename: D J
authors.initials: DJ
authors.lastname: Frey
authors.forename: A J
authors.initials: AJ
authors.lastname: Matas
authors.forename: K J
authors.initials: KJ
authors.lastname: Gillingham
authors.forename: D
authors.initials: D
authors.lastname: Canafax
authors.forename: W D
authors.initials: WD
authors.lastname: Payne
authors.forename: D L
authors.initials: DL
authors.lastname: Dunn
authors.forename: D E
authors.initials: DE
authors.lastname: Sutherland
authors.forename: J S
authors.initials: JS
authors.lastname: Najarian
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002102:Cadaver; D003365:Costs and Cost Analysis; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation / Q000379:methods*; D016853:Muromonab-CD3; D011446:Prospective Studies; D016019:Survival Analysis
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D016853:Muromonab-CD3